Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity

BACKGROUND: Nintedanib, a tyrosine kinase inhibitor that is specific for platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and vascular endothelial growth factor receptors (VEGFR), has recently been approved for idiopathic pulmonary fibrosis. Fibrocytes are...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Seidai, Shinohara, Shintaro, Hayashi, Shinya, Morizumi, Shun, Abe, Shuichi, Okazaki, Hiroyasu, Chen, Yanjuan, Goto, Hisatsugu, Aono, Yoshinori, Ogawa, Hirohisa, Koyama, Kazuya, Nishimura, Haruka, Kawano, Hiroshi, Toyoda, Yuko, Uehara, Hisanori, Nishioka, Yasuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603061/
https://www.ncbi.nlm.nih.gov/pubmed/28915889
http://dx.doi.org/10.1186/s12931-017-0654-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603061/
https://www.ncbi.nlm.nih.gov/pubmed/28915889
http://dx.doi.org/10.1186/s12931-017-0654-2

Ejemplares similares